Teratology and developmental pharmacology: Why should paediatricians care?

Hong Kong Journal of Paediatrics

Volumn 16, Issue 4, 2011, Pages 264-272

  Chung, B H Y ^a   Ip, P ^a   Chow, C B ^a   Chin, R ^b   Lau, Y L ^a   Koren, G ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b KWONG WAH HOSPITAL   (Hong Kong)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Breastfeeding; Congenital malformations; Drug exposed infants; Lactation; Teratology

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; FLUOXETINE; FOLIC ACID; METHADONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TERATOGENIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ARTICLE; BREAST FEEDING; CARDIOVASCULAR MALFORMATION; CHILD DEVELOPMENT; CHILD GROWTH; CHILD HEALTH; CLINICAL EFFECTIVENESS; CONGENITAL MALFORMATION; DEVELOPMENTAL DISORDER; DEVELOPMENTAL PHARMACOLOGY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MILK LEVEL; DRUG USE; ENVIRONMENTAL EXPOSURE; EVIDENCE BASED PRACTICE; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; INFORMATION DISSEMINATION; INFORMATION SERVICE; LACTATION; LIMB DISEASE; LOW BIRTH WEIGHT; MEDICAL PRACTICE; NERVE CELL DIFFERENTIATION; NEURAL TUBE DEFECT; NEUROLOGIC EXAMINATION; NEWBORN DISEASE; PATIENT COUNSELING; PEDIATRICIAN; PHARMACOLOGICAL SCIENCE; PREGNANCY; PREGNANCY OUTCOME; PROFESSIONAL PRACTICE; PROPHYLAXIS; RADIATION DOSE; RADIATION EXPOSURE; RISK ASSESSMENT; RISK FACTOR; SEIZURE; TERATOLOGY; VITAMIN SUPPLEMENTATION;

EID: 80054801979     PISSN: 10139923     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Einarson A. Studying the safety of drugs in pregnancy: and the gold standard is? J Clin Pharmacol Pharmacoepidemiol 2008;1: 3-8.
2. Jacqz-Aigrain E, Koren G. Effects of drugs on the fetus. Semin Fetal Neonatal Med 2005;10:139-47.
3. Law R, Bozzo P, Koren G, Einarson A. FDA pregnancy risk categories and the CPS. Do they help or are they a hindrance? Can Fam Physician 2010;56:239-41.
4. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002;100:465-73.
5. World Health Organization. Unsafe abortion: global and regional estimates of incidence of unsafe abortion and associated mortality in 2000. Geneva: World Health Organization 2004.
6. Guttmacher Institute. Facts on abortion and unintended pregnancy in Asia. New York: Guttmacher Institute 2009; Available from: http://www.guttmacher.org/pubs/IB_AWW-Asia.pdf.
7. Bianca S. Drug use during pregnancy: are risk classifications more dangerous than the drugs? Lancet 2003;362:329.
8. Nordeng H, Ystrom E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol 2010;66:207-14.
9. Organization of Teratology Information Specialists. http://www.otispregnancy.org/. Accessed 11th July 2011.
10. European Network of Teratology Information Services. http:// www.entis-org.com/. Accessed 11th July 2011.
11. Toronto's Motherisk Program. http://www.motherisk.org/.Accessed 11th July 2011.
12. Han JY, Nava-Ocampo AA, Koren G. Unintended pregnancies and exposure to potential human teratogens. Birth Defects Research A Clin Mol Teratol 2005;73:245-8.
13. Hancock RL, Ungar WJ, Einarson A, Goodstadt M, Koren G. Providing information regarding exposures in pregnancy: a survey of North American Teratology Information Services. Reprod Toxicol 2008;25:381-7.
14. Hancock RL, Ungar WJ, Einarson A, Koren G. International practices in the provision of teratology information: a survey of international teratogen information programmes and comparisons with the North American model. J Eval Clin Pract 2010;16: 957-63.
15. Hancock RL, Koren G, Einarson A, Ungar WJ. The effectiveness of Teratology Information Services (TIS). Reprod Toxicol 2007;23:125-32.
16. Einarson A, Portnoi G, Koren G. Update on motherisk updates. Seven years of questions and answers. Can Fam Physician [Research Support, Non-U.S. Gov't]. 2002;48:1301-4.
17. Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I. Major malformations with valproic acid. Can Fam Physician 2006;52:441-2, 4, 7.
18. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-8.
19. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;15:417-20.
20. McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996;10:285-94.
21. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62.
22. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000;30:89-94.
23. Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001;84:F134-5.
24. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-91.
25. Costei AM, Kozer E, Ho T, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32.
26. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354: 579-87.
27. Kalra S, Einarson A, Koren G. Taking antidepressants during late pregnancy. How should we advise women? Can Fam Physician 2005;51:1077-8.
28. Ratnapalan S, Bona N, Koren G. Ionizing radiation during pregnancy. Can Fam Physician 2003;49:873-4.
29. Wood JW, Johnson KG, Omori Y. In utero exposure to the Hiroshima atomic bomb. An evaluation of head size and mental retardation: twenty years later. Pediatrics 1967;39:385-92.
30. Dolk H, Nichols R. Evaluation of the impact of Chernobyl on the prevalence of congenital anomalies in 16 regions of Europe. EUROCAT Working Group. Int J Epidemiol 1999;28:941-8.
31. McCollough CH, Schueler BA, Atwell TD, et al. Radiation exposure and pregnancy: when should we be concerned? Radiographics 2007;27:909-17; discussion 17-8.
32. Bentur Y, Horlatsch N, Koren G. Exposure to ionizing radiation during pregnancy: perception of teratogenic risk and outcome.Teratology 1991;43:109-12.
33. Ratnapalan S, Bona N, Chandra K, Koren G. Physicians' perceptions of teratogenic risk associated with radiography and CT during early pregnancy. AJR Am J Roentgenol 2004;182: 1107-9.
34. Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact 2004;20:62-71.
35. Wojnar-Horton RE, Kristensen JH, Yapp P, Ilett KF, Dusci LJ, Hackett LP. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br J Clin Pharmacol 1997;44:543-7.
36. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006;117:e1163-9.
37. Liu AJ, Nanan R. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008;121:869; author reply-70.
38. Meites E. Opiate exposure in breastfeeding newborns. J Hum Lact 2007;23:13.
39. American Academy of Pediatrics, Committee on Drugs. The transfer of drugs and other chemicals into human breast milk.Pediatrics 1983;72:375-83.
40. American Academy of Pediatrics, Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
41. Center for Substance Abuse Treatment. Improving Treatment for Drug-Exposed Infants. Rockville, MD: Substance Abuse and Mental Health Services Administration 1993.
42. Mezzacappa ES, Kelsey RM, Katkin ES. Breast feeding, bottle feeding, and maternal autonomic responses to stress. J Psychosom Res 2005;58:351-65.
43. Malpas TJ, Meates J, Horwood J, Darlow BA. How safe is antenatal transfer between level 3 units? Aust N Z J Obstet Gynaecol 1997;37:258-60.
44. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991;338:131-7.
45. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med [Clinical Trial Randomized Controlled Trial] 1992; 327:1832-5.
46. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane database of systematic reviews. 2001(3):CD001056.
47. Anonymous. U.S. Preventive Services Task Force: Folic acid for the prevention of neural tube defects: recommendation statment. Am Fam Physician 2010;82:53.
48. Koren G, Goh YI, Klieger C. Folic acid: the right dose. Can Fam Physician 2008;54:1545-7.
49. Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet 2001;358:2069-73.
50. Kim YI. Does a high folate intake increase the risk of breast cancer? Nutr Rev 2006;64(10 Pt 1):468-75.
51. Hong Kong Census Data. http://www.censtatd.gov.hk/hong_kong_statistics/statistical_tables/index.jsp?tableID=004. Accessed 11th July 2011.
52. Gallo M, Einarson A, Koren G. Herbal medicine use in pregnancy: a new frontier in clinical teratology. Birth Defects Res B Dev Reprod Toxicol 2003;68:499-500.
53. Hospital Authority, Hong Kong. Enhancing Pre-Hospital Poisoning Consultation and Treatment Services 2010: Available from: http://www.hkpcn.org.hk/.
54. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398-407.
55. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000;20:399-403.
56. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. A J Psychiatry 2002;159:1889-95.
57. Tiran D. The use of herbs by pregnant and childbearing women: a risk-benefit assessment. Complement Ther Nurs Midwifery 2003;9:176-81.
58. van Trigt AM, Waardenburg CM, Haaijer-Ruskamp FM, de Jong-van den Berg LT. Questions about drugs: how do pregnant women solve them? Pharm World Sci 1994;16:254-9.
59. Clementi M, Di Gianantonio E, Ornoy A. Teratology information services in Europe and their contribution to the prevention of congenital anomalies. Community Genet 2002;5:8-12.
60. Webster WS, Freeman JA. Is this drug safe in pregnancy? Reprod Toxicol [Review] 2001;15:619-29.
61. Koren G, Pastuszak A. Teratogen Information Service. In: Koren G, editor. Maternal-fetal toxicology: a clinician's guide. 2nd ed.New York: Marcel Dekker; 1994. p.683-705.
62. Einarson A, Bailey B, Jung G, Spizzirri D, Baillie M, Koren G. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology. [Research Support, Non-U.S. Gov't] 1997; 78:183-6.
63. Koren G, Pastuszak A. Prevention of unnecessary pregnancy terminations by counselling women on drug, chemical, and radiation exposure during the first trimester. Teratology 1990; 41:657-61.
64. De Santis M, Straface G, Cavaliere A, Cinque B, Carducci B, Caruso A. Teratological risk evaluation and prevention of voluntary abortion. Minerva Ginecol 2006;58:91-9.
65. Robbins JM, Cleves MA, Collins HB, Andrews N, Smith LN, Hobbs CA. Randomized trial of a physician-based intervention to increase the use of folic acid supplements among women. Am J Obstet Gynecol 2005;192:1126-32.
66. Pastuszak A, Bhatia D, Okotore B, Koren G. Preconception counseling and women's compliance with folic acid supplementation. Can Fam Physician 1999;45:2053-7.
67. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001;26:44-8.
68. Pole M, Einarson A, Pairaudeau N, Einarson T, Koren G. Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals. J Clin Pharmacol 2000;40:573-7.
69. Ito S, Lieu M, Chan W, Koren G. Continuing drug therapy while breastfeeding. Part 1. Common misconceptions of patients. Can Fam Physician 1999;45:897-9.
70. Viguera AC, Cohen LS, Bouffard S, Whitfield TH, Baldessarini RJ. Reproductive decisions by women with bipolar disorder after prepregnancy psychiatric consultation. A J Psychiatry 2002;159: 2102-4.
71. Einarson A, Park A, Koren G. How physicians perceive and utilize information from a teratogen information service: the Motherisk Program. BMC Med Educ 2004;4:6.
72. Ratnapalan S, Bentur Y, Koren G. "Doctor, will that X-ray harm my unborn child?". Can Med Assoc J 2008;179:1293-6.